Literature DB >> 23538341

Preapoptotic protease calpain-2 is frequently suppressed in adult T-cell leukemia.

Makoto Ishihara1, Natsumi Araya, Tomoo Sato, Ayako Tatsuguchi, Naomi Saichi, Atae Utsunomiya, Yusuke Nakamura, Hidewaki Nakagawa, Yoshihisa Yamano, Koji Ueda.   

Abstract

Adult T-cell leukemia (ATL) is one of the most aggressive hematologic malignancies caused by human T-lymphotropic virus type 1 (HTLV-1) infection. The prognosis of ATL is extremely poor; however, effective strategies for diagnosis and treatment have not been established. To identify novel therapeutic targets and diagnostic markers for ATL, we employed focused proteomic profiling of the CD4(+)CD25(+)CCR4(+) T-cell subpopulation in which HTLV-1-infected cells were enriched. Comprehensive quantification of 14 064 peptides and subsequent 2-step statistical analysis using 29 cases (6 uninfected controls, 5 asymptomatic carriers, 9 HTLV-1-associated myelopathy/tropical spastic paraparesis patients, 9 ATL patients) identified 91 peptide determinants that statistically classified 4 clinical groups with an accuracy rate of 92.2% by cross-validation test. Among the identified 17 classifier proteins, α-II spectrin was drastically accumulated in infected T cells derived from ATL patients, whereas its digestive protease calpain-2 (CAN2) was significantly downregulated. Further cell cycle analysis and cell growth assay revealed that rescue of CAN2 activity by overexpressing constitutively active CAN2 (Δ(19)CAN2) could induce remarkable cell death on ATL cells accompanied by reduction of α-II spectrin. These results support that proteomic profiling of HTLV-1-infected T cells could provide potential diagnostic biomarkers and an attractive resource of therapeutic targets for ATL.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23538341      PMCID: PMC3663426          DOI: 10.1182/blood-2012-08-446922

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  29 in total

1.  Development of serum glycoproteomic profiling technique; simultaneous identification of glycosylation sites and site-specific quantification of glycan structure changes.

Authors:  Koji Ueda; Sachiko Takami; Naomi Saichi; Yataro Daigo; Nobuhisa Ishikawa; Nobuoki Kohno; Masaru Katsumata; Akio Yamane; Minoru Ota; Taka-Aki Sato; Yusuke Nakamura; Hidewaki Nakagawa
Journal:  Mol Cell Proteomics       Date:  2010-09       Impact factor: 5.911

2.  Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study.

Authors:  Takashi Ishida; Tatsuro Joh; Naokuni Uike; Kazuhito Yamamoto; Atae Utsunomiya; Shinichiro Yoshida; Yoshio Saburi; Toshihiro Miyamoto; Shigeki Takemoto; Hitoshi Suzushima; Kunihiro Tsukasaki; Kisato Nosaka; Hiroshi Fujiwara; Kenji Ishitsuka; Hiroshi Inagaki; Michinori Ogura; Shiro Akinaga; Masao Tomonaga; Kensei Tobinai; Ryuzo Ueda
Journal:  J Clin Oncol       Date:  2012-02-06       Impact factor: 44.544

3.  Identification of a de novo thymidylate biosynthesis pathway in mammalian mitochondria.

Authors:  Donald D Anderson; Cynthia M Quintero; Patrick J Stover
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-26       Impact factor: 11.205

Review 4.  The calpain system and cancer.

Authors:  Sarah J Storr; Neil O Carragher; Margaret C Frame; Tim Parr; Stewart G Martin
Journal:  Nat Rev Cancer       Date:  2011-05       Impact factor: 60.716

5.  Proteomics-based signature for human benign prostate hyperplasia and prostate adenocarcinoma.

Authors:  Ayodele A Alaiya; Mai Al-Mohanna; Muhammad Aslam; Zakia Shinwari; Layla Al-Mansouri; Maha Al-Rodayan; Maha Al-Eid; Irfan Ahmad; Kamal Hanash; Asma Tulbah; Ali Bin Mahfooz; Chaker Adra
Journal:  Int J Oncol       Date:  2011-02-08       Impact factor: 5.650

6.  Proteomics and pitfalls in the search for potential biomarkers of abdominal aortic aneurysms.

Authors:  Ian M Nordon; Ranjeet Brar; Robert J Hinchliffe; Gillian Cockerill; Matthew M Thompson
Journal:  Vascular       Date:  2010 Sep-Oct       Impact factor: 1.285

7.  Expression of a protein involved in bone resorption, Dkk1, is activated by HTLV-1 bZIP factor through its activation domain.

Authors:  Nicholas Polakowski; Heather Gregory; Jean-Michel Mesnard; Isabelle Lemasson
Journal:  Retrovirology       Date:  2010-07-23       Impact factor: 4.602

8.  A comprehensive peptidome profiling technology for the identification of early detection biomarkers for lung adenocarcinoma.

Authors:  Koji Ueda; Naomi Saichi; Sachiko Takami; Daechun Kang; Atsuhiko Toyama; Yataro Daigo; Nobuhisa Ishikawa; Nobuoki Kohno; Kenji Tamura; Taro Shuin; Masato Nakayama; Taka-Aki Sato; Yusuke Nakamura; Hidewaki Nakagawa
Journal:  PLoS One       Date:  2011-04-12       Impact factor: 3.240

9.  Plasma proteome analysis in HTLV-1-associated myelopathy/tropical spastic paraparesis.

Authors:  Paul D W Kirk; Aviva Witkover; Alan Courtney; Alexandra M Lewin; Robin Wait; Michael P H Stumpf; Sylvia Richardson; Graham P Taylor; Charles R M Bangham
Journal:  Retrovirology       Date:  2011-10-12       Impact factor: 4.602

10.  Abnormally high levels of virus-infected IFN-gamma+ CCR4+ CD4+ CD25+ T cells in a retrovirus-associated neuroinflammatory disorder.

Authors:  Yoshihisa Yamano; Natsumi Araya; Tomoo Sato; Atae Utsunomiya; Kazuko Azakami; Daisuke Hasegawa; Toshihiko Izumi; Hidetoshi Fujita; Satoko Aratani; Naoko Yagishita; Ryoji Fujii; Kusuki Nishioka; Steven Jacobson; Toshihiro Nakajima
Journal:  PLoS One       Date:  2009-08-05       Impact factor: 3.240

View more
  6 in total

1.  Gene expression profiling of idiopathic interstitial pneumonias (IIPs): identification of potential diagnostic markers and therapeutic targets.

Authors:  Yasushi Horimasu; Nobuhisa Ishikawa; Masaya Taniwaki; Kakuhiro Yamaguchi; Kosuke Hamai; Hiroshi Iwamoto; Shinichiro Ohshimo; Hironobu Hamada; Noboru Hattori; Morihito Okada; Koji Arihiro; Yuji Ohtsuki; Nobuoki Kohno
Journal:  BMC Med Genet       Date:  2017-08-18       Impact factor: 2.103

2.  A Fashi Lymphoproliferative Phenotype Reveals Non-Apoptotic Fas Signaling in HTLV-1-Associated Neuroinflammation.

Authors:  Soraya Maria Menezes; Fabio E Leal; Tim Dierckx; Ricardo Khouri; Daniele Decanine; Gilvaneia Silva-Santos; Saul V Schnitman; Ramon Kruschewsky; Giovanni López; Carolina Alvarez; Michael Talledo; Eduardo Gotuzzo; Douglas F Nixon; Jurgen Vercauteren; David Brassat; Roland Liblau; Anne Mieke Vandamme; Bernardo Galvão-Castro; Johan Van Weyenbergh
Journal:  Front Immunol       Date:  2017-02-14       Impact factor: 7.561

3.  Integrated epigenetic and genetic analysis identifies markers of prognostic significance in pediatric acute myeloid leukemia.

Authors:  Jatinder K Lamba; Xueyuan Cao; Susana C Raimondi; Roya Rafiee; James R Downing; Shi Lei; Tanja Gruber; Raul C Ribeiro; Jeffrey E Rubnitz; Stanley B Pounds
Journal:  Oncotarget       Date:  2018-06-01

4.  Differences in the expression of chromosome 1 genes between lung telocytes and other cells: mesenchymal stem cells, fibroblasts, alveolar type II cells, airway epithelial cells and lymphocytes.

Authors:  Xiaoru Sun; Minghuan Zheng; Miaomiao Zhang; Mengjia Qian; Yonghua Zheng; Meiyi Li; Dragos Cretoiu; Chengshui Chen; Luonan Chen; Laurentiu M Popescu; Xiangdong Wang
Journal:  J Cell Mol Med       Date:  2014-05       Impact factor: 5.310

5.  Regulatory network analysis reveals the oncogenesis roles of feed-forward loops and therapeutic target in T-cell acute lymphoblastic leukemia.

Authors:  Mengxuan Xia; Qiong Zhang; Mei Luo; Pan Li; Yingxue Wang; Qian Lei; An-Yuan Guo
Journal:  BMC Med Genomics       Date:  2019-01-15       Impact factor: 3.063

6.  Meta-Analysis of HTLV-1-Infected Patients Identifies CD40LG and GBP2 as Markers of ATLL and HAM/TSP Clinical Status: Two Genes Beat as One.

Authors:  Eduardo Rocha Fukutani; Pablo Ivan Pereira Ramos; José Irahe Kasprzykowski; Lucas Gentil Azevedo; Moreno Magalhães de Souza Rodrigues; João Victor de Oliveira Pimenta Lima; Helton Fábio Santos de Araújo Junior; Kiyoshi Ferreira Fukutani; Artur Trancoso Lopo de Queiroz
Journal:  Front Genet       Date:  2019-11-08       Impact factor: 4.599

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.